Judges Removable-At-Will Is Better Than No PTAB At All

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
On March 23, 2020, the Federal Circuit issued a per curiam order denying rehearing and rehearing en banc in Arthrex. See Arthrex, Inc. v. Smith & Nephew, Inc....
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

On March 23, 2020, the Federal Circuit issued a per curiam order denying rehearing and rehearing en banc in Arthrex. See Arthrex, Inc. v. Smith & Nephew, Inc., No. 18-2140, Order Denying Rehearing and Rehearing En Banc, Dkt. 115. We have discussed this most recent development in the Arthrex case in our earlier posts this week: BREAKING: Arthrex Rehearing Denied, Arthrex en banc Denied – The Big Picture , and Judges Disagree on Arthrex, But Rehearing Vote Fails.

The Federal Circuit's per curiam order is accompanied by five separate opinions: two concurrences and three dissents. Judge Moore wrote the first concurrence which was joined by Judges O'Malley, Reyna, and Chen.

Judge Moore's concurrence started from the Arthrex panel's conclusion that that the PTAB's administrative patent judges (APJs) were improperly appointed principal officers, and defended the thesis that the proper fix for constitutional issue was to "sever[] any problematic portions while leaving the remainder intact." In particular, Judge Moore explained that severing the APJs' removal protections was the right remedy, because it was the narrowest possible modification and would only minimally affect the operation of the current IPR system.

In Judge Moore's view, Congress' basic objective in creating the IPR system was to provide "an agency mechanism where the validity of issued patents may be challenged." Removal protections for the APJs were not the central objective of Congress, who "would have preferred a Board whose members are removable at will rather than no Board at all." She therefore saw the severance of removal protections as a much preferred alternative over "the entire thing being struck down as unconstitutional."

Judicial economy was also an important consideration to Judge Moore. She emphasized that under the severance applied in Arthrex, "no more than 81 appeals including Arthrex itself can be vacated and remanded." In contrast, some of the other fixes would result in "an unnecessary backlog of cases."

Judge Moore was critical of the approach in Judge Dyk's dissent, which proposed staying the case while Congress considers a restructuring of the PTAB to include a reconsideration panel. She doubted if the proposed fix would actually pass constitutional muster. In any case, such "legislative or regulatory advisory mandates," according to Judge Moore, were beyond the court's limited "constitutional mandate and institutional competence." "We should not attempt to correct a separation of powers issue by creating one of our own," she wrote.

Finally, Judge Moore noted that the Arthrex decision does not prevent Congress from legislating an alternative fix to the Appointments Clause issue. Congress can still reinstate the removal protections for APJs while ensuring compliance with the Appointments Clause.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More